Association of HLA mismatch and MTOR inhibitor regimens with malignancy and mortality after kidney transplantation

Abstract

BackgroundThe association of mammalian target of rapamycin inhibitors (MTORI) with malignancies and mortality in kidney transplant recipients (KTR) with different degrees of human leukocyte antigen mismatch (HLA-mm) at transplant has not been previously studied.MethodsOur observational cohort study included 166, 256 adult KTRs in 2000–2018. Immunosuppression in the first post-transplant year were MTORIs in 13,056 (7.85%) and non-MTORIs in 153,200 (92.15%). We used Cox multivariable regression models to determine the cause-specific hazard ratio (HRcs) of non-melanoma skin cancer (NMSC),solid organ malignancies (SOM)] and all-cause death (deathac); and the HR of the composite outcomes of NMSC or deathac and SOM or deathac associated with MTORI versus non-MTORI regimens in the overall study sample and the 0, 1–3, and 4–6 HLA-A, B and DR mm subgroups.ResultsNMSC risk was lower with MTORI than non-MTORI in all HLA-mm subgroups [(0 mm, HRcs = 0.67; 95% CI = 0.46–0.97, 1–3 mm, HRcs = 0.73; 95% CI = 0.61–0.87, 4–6 mm, HRcs = 0.69; 95% CI = 0.62–0.76)]. SOM risks were similar between regimens in the 0 HLA mm subgroup (HRcs = 1.10 (95% CI = 0.78–1.57) and lower with MTORI than non-MTORI in the 1–3, and 4–6 HLA-mm subgroups, [(HR = 0.84; (95% CI = 0.71–0.99), and (HR = 0.86; 95% CI = 0.78–0.94); respectively]. Risks of deathac and composite outcomes (NMSC or deathac and SOM or deathac) were higher with MTORI than non-MTORI in almost all HLA-mm subgroups.ConclusionMTORIs are associated with protection from NMSC and SOM in almost all HLA-mm subgroups ca; however, their association with increased all-cause mortality in adult kidney transplant recipients needs further investigation.